Who controls your cortex

“Who controls your cortex?” is the question Timothy Leary and Richard Alpert put to students as they announced a break with Harvard’s oversight of psychedelic research. Its significance lies in how it turns a dispute over research restrictions into a question about authority over consciousness: who may investigate it, set its limits, or decide which forms of awareness are permissible?

Origin and Audience

At the end of 1962, Leary and Alpert said they would conduct their work under the International Federation for Internal Freedom rather than Harvard. Their letter to the Crimson framed the change as a response to restrictions on psychedelic research at both the university and federal levels. The question about the cortex was addressed directly to students, inviting them to consider whether they themselves should be able to research their nervous systems and expand their consciousness.

The letter placed this challenge in a civil-liberties frame. Leary and Alpert argued that the control and expansion of consciousness would become a major political issue, and described the new constraints as creating a scientific underground. In that setting, “Who controls your cortex?” was not merely a provocative slogan: it recast regulation of experimental drugs as a dispute over who could claim jurisdiction over inner experience.

A Challenge to Psychiatric Authority

The question also illuminates why psychedelic therapy unsettled established psychiatry. Earlier models could be accommodated within familiar professional ideas: one treated the drugs’ effects as resembling psychosis, while another used them as an adjunct to psychoanalysis. Psychedelic therapy, by contrast, proposed a single high-dose session aimed at a conversion experience, unsettling customary distinctions between patient and therapist, sickness and health, and scientific treatment and religious experience.

Its emphasis on set and setting further complicated the claim that a drug could be evaluated apart from the experience organized around it. Charles Grob characterized the approach as applied mysticism, while Franz Vollenweider described its shamanic elements as outside a conventional medical concept. The question about who controls the cortex thus resonates with a deeper professional conflict: whether mental health care should be understood solely through biochemical effects, or should also account for meaning, context, and the guided experience itself.

Knowledge Outside the Laboratory

The phrase’s challenge to institutional control acquired a practical counterpart in underground psychedelic therapy. Many guides interviewed by the book traced their professional lineages to earlier practitioners, including Leo Zeff, Al Hubbard, Stanislav Grof, and Timothy Leary or his students. Zeff continued working underground after the federal scheduling of psychedelics in 1970, and his practices helped shape the informal protocols used by guides.

Those protocols included strict confidentiality, a prohibition on sexual contact, and clear agreements about following the guide’s instructions during a session. Zeff also believed guides should have personal experience with the medicines they administered, avoid steering a client’s journey, and offer personal warmth rather than maintain the conventional analyst’s detachment. These practices located therapeutic authority not only in formal institutions or professional credentials, but also in a guide’s experience, conduct, and relationship with the person undergoing treatment.

From Protest to a New Therapeutic Framework

The later research revival did not simply resolve the dispute between institutional medicine and alternative practice. Researchers argued that rigorous methods remained necessary, but that psychedelic treatment also required attention to the experience and the conditions surrounding it. Grob called for research designs to consider what successful applications of the shamanic paradigm could teach about set, setting, and the medicines’ suggestive properties.

Jeffrey Guss described psychedelic therapy as a joining of biologically based and psychodynamic approaches, bringing together questions of brain chemistry and loss of meaning. At a later conference, former mental-health leaders recognized psychedelic-assisted psychotherapy as a novel model, while warning that safety, rigor, and public trust could be put at risk by careless research or a disastrous patient experience. Against this later backdrop, the original question remains pointed but not self-answering: it identifies a contest over who may study and guide consciousness, without implying that institutional safeguards or therapeutic responsibility can simply be discarded.